During a 2025 DCAT Week exclusive panel experts from across the sector, including two of our own, Jessica Feldman, Director Process Science, and Henning Gerschewski, VP Manufacturing Science & Technology, discussed how collaboration and innovation are reshaping the path to commercial readiness.
While the COVID-19 pandemic compelled the industry to improve supply chain resiliency and vendor diversity, it also exposed the fragility of scale-up capabilities under pressure. Foundational lessons have been learned, but the complexity of achieving efficient, reproducible, and accelerated scale-up remains an ongoing challenge. At Rentschler Biopharma, we view scale-up not just as a technical milestone but as a pivotal inflection point in a therapy’s journey.
Several key takeaways were highlighted during the panel discussion:
As the industry adopts advanced platforms and smarter technologies, the path forward is clear: those who can flex will lead. With a global network and digitally enabled infrastructure, Rentschler Biopharma is uniquely positioned to support clients at every stage of their journey, from first-in-human to commercial launch, because in biologics manufacturing, scale isn’t just about size. It’s about readiness.
Download the VIP Panel Summary here:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications